Quinn Opportunity Partners LLC
Position in REPL — Replimune Group, Inc.
CIK 1633275
CHARLOTTESVILLE, VA
Position in REPL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,201,631
-$1,617,502 QoQ
Shares Held
287,795
-26.8% QoQ
Ownership
0.343%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 71.46649524835387.ToString("F0")%
Shared 0.ToString("F0")%
None 28.533504751646138.ToString("F0")%
Common Shares in REPL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Quinn Opportunity Partners LLC holds $55,803,564 across 25 Biotechnology names. REPL ranks #5 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BNTX |
BioNTech SE
|
228,832 | $20,338,588 | |
| 2 | NKTR |
Nektar Therapeutics
|
179,247 | $12,896,821 | |
| 3 | CAPR |
Capricor Therapeutics, Inc.
|
178,383 | $5,422,843 | |
| 4 | ABUS |
Arbutus Biopharma Corp
|
514,513 | $2,315,308 | |
| 5 | REPL |
Replimune Group, Inc.
This page
|
287,795 | $2,201,631 | |
| 6 | ABVX |
Abivax S.A.
|
16,000 | $1,781,600 | |
| 7 | SPRB |
Spruce Biosciences, Inc.
|
26,810 | $1,752,033 | |
| 8 | SPRY |
ARS Pharmaceuticals, Inc.
|
155,000 | $1,244,650 |
All Filings in REPL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,201,631 | 287,795 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,819,133 | 392,915 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $2,726,520 | 650,721 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||